• Feedback
  • RSS Feed
  • Sitemap
Ommcom News
  • Home
  • Odisha
  • Nation
  • World
  • Sports
  • Business
  • Entertainment
  • Videos
  • Science & Tech
  • Photo Gallery
  • ଓଡ଼ିଆରେ ପଢନ୍ତୁ
No Result
View All Result
  • Home
  • Odisha
  • Nation
  • World
  • Sports
  • Business
  • Entertainment
  • Videos
  • Science & Tech
  • Photo Gallery
  • ଓଡ଼ିଆରେ ପଢନ୍ତୁ
No Result
View All Result
Odisha News, Odisha Breaking News, Odisha Latest News || Ommcom News
Home World

Global HIV Market To Cross $32 Billion In 7 Major Markets In 2033: Report

OMMCOM NEWS by OMMCOM NEWS
May 11, 2025
in World

New Delhi: A new report has said that the human immunodeficiency virus (HIV) market across the seven major markets is forecast to grow at a compound annual growth rate (CAGR) of 1.9 per cent from $26.5 billion in 2023 to $32.1 billion in 2033.

The GlobalData’s report, “Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast,” reveals that market growth will primarily be driven by the increased uptake of long-acting injectable therapies, as well as the anticipated launch of novel single tablet regimens (STRs).

“The pipeline analysis indicates a shift away from 3-drug STRs and towards 2-drug STRs. These are hoped to have reduced toxicities and side effects as a result,” said Anaelle Tannen, Infectious Disease Analyst at GlobalData.

Six products are currently in Phase III development and are expected to launch by 2033, including four two-drug STRs.

These are Gilead Sciences’ (Gilead) once-daily combination of bictegravir and lenacapavir, Merck’s once-daily doravirine and islatravir, Gilead’s once-weekly islatravir and lenacapavir, and a once-weekly regimen of GS-1720 and GS-4182 developed jointly by Gilead and Merck.

“Currently, all STRs require daily administration and there is a need for alternative and more convenient options for patients which islatravir+lenacapavir and GS-1720+GS-4182 could address,” said Tannen.

Other notable therapies in late-stage development include CytoDyn’s once-weekly leronlimab, which is expected to be used in patients with CCR5-type virus, and Gilead’s biannual injectable lenacapavir for pre-exposure prophylaxis (PrEP).

Long-acting injectable therapies will gain significant market share across the 7MM as this method requires infrequent dosing and is thus more convenient.

“Lenacapavir, for example, is initially expected to be administered subcutaneously biannually for PrEP, and clinical trials are underway to see its efficacy when administered once a year. Data from a Phase I trial has demonstrated lenacapavir’s potential when administered intramuscularly once yearly,” Tannen informed.

Subcutaneous lenacapavir has demonstrated 100 per cent efficacy in preventing new HIV infections and, thus, has shown its potential as an important new tool for PrEP.

However, subcutaneous lenacapavir is expected to be more expensive than daily oral PrEP and the key opinion leaders (KOLs) interviewed by GlobalData have highlighted that this may be a barrier to access.

(IANS)

ShareTweetSendSharePinShareSend
Previous Post

Popular Govt In Manipur In Two Months, Says BJP MP

Next Post

Indo-Pak Tension: Special Prayers Held In Mizoram In Solidarity With Armed Forces

Related Posts

World

Iran Launches Missiles Against US Bases In Iraq & Qatar, No Major Damage Reported

June 23, 2025
World

‘Security Of Nuclear Facilities Is High Priority’: India On Iran-Israel Conflict

June 23, 2025
World

China-Pakistan-Bangladesh Axis Poses New Challenge In Subcontinent

June 23, 2025
World

Unprovoked Aggression Against Iran Lacks Justification: Putin

June 23, 2025
Vladimir Putin
World

Russian President, Iraqi PM Discuss Regional Tensions Over Phone

June 23, 2025
World

Iranian FM Discusses US Attacks On Nuclear Sites With French, Italian Counterparts

June 23, 2025
Next Post

Indo-Pak Tension: Special Prayers Held In Mizoram In Solidarity With Armed Forces

Kynan, Sabeera, Win Trap Mixed Team Bronze As Nicosia Shotgun World Cup Concludes

Rourkela Police

Rourkela Police Arrest One In Bike Theft Case

Khimji
OMC
  • Feedback
  • RSS Feed
  • Sitemap

© 2025 - Ommcom News. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Home
  • Odisha
  • Nation
  • World
  • Sports
  • Business
  • Entertainment
  • Videos
  • Science & Tech
  • Photo Gallery
  • ଓଡ଼ିଆରେ ପଢନ୍ତୁ

© 2025 - Ommcom News. All Rights Reserved.